Quick Answer
XBiotech Inc. reported Operating Income Loss of -$55.69 million for the year ending 2025.
- XBiotech Inc. showed a decrease of -31.1% in Operating Income Loss from 2024 to 2025.
- This data is from XBiotech Inc.'s annual report (Form 10-K), filed with the SEC on March 13, 2026.
- XBRL data for this metric is available from 2013 to 2025 (13 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2015: -$8.21 million | Q2 2015: $6.42 million | Q3 2015: $10.81 million | Q1 2016: -$10.25 million | Q2 2016: -$13.62 million | Q3 2016: -$12.46 million | Q4 2016: -$16.44 million | Q1 2017: -$10.27 million | Q2 2017: -$9.69 million | Q3 2017: -$6.59 million | Q4 2017: -$7.51 million | Q1 2018: -$4.15 million | Q2 2018: -$5.62 million | Q3 2018: -$5.12 million | Q4 2018: -$6.11 million | Q1 2019: -$5.81 million | Q2 2019: -$6.01 million | Q3 2019: -$6.11 million | Q4 2019: -$13.31 million | Q1 2020: -$2.17 million | Q2 2020: -$6.51 million | Q3 2020: -$4.67 million | Q4 2020: -$4.92 million | Q1 2021: -$3.55 million | Q2 2021: -$10.61 million | Q3 2021: -$3.73 million | Q4 2021: -$7.19 million | Q1 2022: -$7.85 million | Q2 2022: -$12.09 million | Q3 2022: -$6.39 million | Q4 2022: -$8.16 million | Q1 2023: -$7.15 million | Q2 2023: -$13.26 million | Q3 2023: -$8.52 million | Q4 2023: -$8.59 million | Q1 2024: -$10.85 million | Q2 2024: -$14.97 million | Q3 2024: -$7.90 million | Q1 2025: -$13.55 million | Q2 2025: -$6.34 million | Q3 2025: -$6.05 million.
- Over the full 13 years of available data (2013 to 2025), XBiotech Inc.'s Operating Income Loss has declined by 461.1%.
- Historical annual values: Fiscal year 2025: -$55.69 million | Fiscal year 2024: -$42.47 million | Fiscal year 2023: -$37.51 million | Fiscal year 2022: -$34.49 million | Fiscal year 2021: -$25.08 million | Fiscal year 2020: -$18.28 million | Fiscal year 2019: -$31.23 million | Fiscal year 2018: -$20.99 million | Fiscal year 2017: -$34.06 million | Fiscal year 2016: -$52.76 million | Fiscal year 2015: -$37.51 million | Fiscal year 2014: -$21.78 million | Fiscal year 2013: -$9.93 million.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: